|
|
|
|
Cancer biotherapy
An introductory guide
Edited by Annie Young, Lewis Rowett, and David Kerr
336 pages
|
Numerous tables and line drawings
|
234x156mm
978-0-19-856631-1
|
Paperback
|
04 May 2006
|
|
This item is printed to order. Items which are printed to order are normally despatched and charged within 5-10 days.
|
|
|
- An invaluable introduction to the subject written by a multidisciplinary team of experts
- Includes clinically focused guidelines on the use of biotherapy to treat cancer
- Contains clear descriptions of mechanisms for new anticancer therapies
- Provides a comprehensive background for oncologists and all clinical staff faced with new agents
Recent advances in biology and immunology have opened up new horizons in both our understanding of cancer as a disease, and the potential for cancer therapy. These major developments mean that chemotherapy, radiotherapy and surgery are no longer the only options. Biotherapy, or biological therapy, is now regarded as the fourth treatment modality for patients with cancer. It utilises the great increase in our knowledge of molecular biology, cell biology and immunology to achieve tumour control.
New biological agents are currently being used to treat cancer, such as monoclonal antibodies and
vaccine therapies to stimulate the body's immune system to attack cancer cells. Biotherapy may be targeted to act specifically on cancer cells. Drugs such as monoclonal antibodies can be designed to recognize and find a particular type of cancer cell, attach itself to them, and destroy them. Naturally occuring biological molecules such as cytokines are also used, and the manipulation of normal biological mechanisms to control or inhibit tumour growth is another key feature of biotherapy.
Edited by a team with perspectives in pharmacology, oncology and nursing, and with contributions from experts in the various areas of biotherapy, this book serves as an introduction to the subject. It includes the principles behind biological therapy, with discussion of the impact
on the future of the fight against cancer. It has a strong clinical focus, describing the relevant biology and immunology while highlighting clinical relevance and treatment issues.Readership: This introduction to the subject is aimed primarily at medical students, trainee oncologists and haematologists, physicians not specializing in oncology, and specialist nurses.
|
|
|
Edited by Annie Young, Nurse Director, Three Counties Cancer Network, St Paul's Medical Centre, Cheltenham, UK, Lewis Rowett, Executive Editor, Annals of Oncology, ESMO Head Offce, Viganello-Lugano, Switzerland, and David Kerr, Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics, University of Oxford; Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford, UK Contributors:
Kenneth D Bagshawe, Department of Medical Oncology, Imperial College, London, UK
Richard H J Begent, Department of Oncology, University College London, UK
Deborah Beirne, Cancer Medicine
Research Unit, St James Hospital, Leeds, UK
Peter Borchmann, Medizinische Einrichtungen der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany
Aniruddha Choudhury, Immune and Gene Therapy Laboratory, Karolinska University Hospital, Stockholm, Sweden
Andreas Engert, Medizinische Einrichtungen der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany
David Kerr, Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford, UK
Dirk Laurent, Schering AG, SBU Specialized Therapeutics, Corporate Clinical Development Therapeutics Europe, Berlin, Germany
Wan-Teck Lim, National Cancer Centre Singapore, Republic of Singapore
Howard L McLeod, Washington University School of Medicine, St Louis,
Missouri, USA
Håkan Mellstedt, Departments of Oncology and Hematology, Karolinska University Hospital, Stockholm, Sweden
Rachel Midgley, Cancer Research UK, Churchill Hospital, Oxford, UK
Monica M Mita, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA
Kees Nooter, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Cornelius J A Punt, Department of Medical Oncology. Radboud University Medical Centre Nijmegen, The Netherlands
Lewis Rowett, Annals of Oncology, ESMO Head Office, Viganello-Lugano, Switzerland
Eric K Rowinsky, Imclone Systems, Branchburg, New Jersey, USA
Gary K Schwartz, Laboratory of
New Drug Development, Memorial Sloan-Kettering Cancer Center, New York, USA
Leonard Seymour, Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, UK
Manish A Shah, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA
Surinder K Sharma, Department of Oncology, University College London, UK
Stefan Sleijfer, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Neil Steven, CRC Institute for Cancer Studies, The Medical School, University of Birmingham, UK
Archie Tse, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA
Carla M L van Herpen, Department of Medical
Oncology. Radboud University Medical Centre Nijmegen, The Netherlands
Jaap Verwejj, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Annie Young, Three Counties Cancer Network, Cheltenham, UK
|
|
|
"The editors of this new book...provide a good introductory guide to a whole range of biological interventions. The authors do make the very important point that 'individualised' treatment is going to be the order of the day. All cancer are different, we have to find out how different they are with ever-improving laboratory testing, and we have to tailor treatment to suit each cancer's unique profile and bring them back under control biologically." - Oncology News, Vol 1 Issue 5, "This introductory guide is essential reading as the transition from the laboratory phase to clinical practice is made. Opening chapters on the cell biology of caner and the immune system set the scene, before the clinical development of biological
therapies is addressed. The reader is then guided through the various methods and types of biological therapy...The potential of genetic information to benefit patients concludes this guide. [It is] edited by a team with perspectives in pharmacology, oncology and nursing, and [has] contributions from experts in the various areas of biotherapy."
|
|
|
David Kerr, Lewis Rowett & Annie Young: Introduction
1: Lewis Rowett & Annie Young: An introduction to the cell biology of cancer
2: Rachel Midgley: An introduction to the immune system and cancer
3: David Kerr: The clinical development of biologic therapies
4: Stefan Sleijfer, Kees Nooter & Jaap Verwejj: Kinase inhibitors
5: Monica M Mita & Eric K Rowinsky: The RAS pathway - a target for anticancer therapy
6: Manish A Shah, Archie Tse & Gary K Schwartz: The development of cell cycle active agents for cancer therapy
7: Peter Borchmann & Andreas Engert: Therapeutic monoclonal antibodies
8: Surinder K Sharma, Kenneth D Bagshawe & Richard H J Begent: Antibody Directed Enzyme Prodrug Therapy (ADEPT)
9: Carla M L van Herpen & Cornelius J A Punt: Cytokines
10: Dirk Laurent: Inhibitors of invasion and angiogenesis
11: Aniruddha Choudhury & Håkan Mellstedt: Proteins, peptides and DNA vaccines for cancer
12: Neil Steven: Cell based immunotherapy
13: Deborah Beirne & Leonard Seymour: Gene therapy for cancer - approaches and ethical considerations
14: Wan-Teck Lim & Howard L McLeod: Individualising cancer therapy
Glossary
|
|
|
|
|
|
|
|
|
The specification in this catalogue, including without limitation price, format, extent, number of illustrations, and month of publication, was as accurate as possible at the time the catalogue was compiled. Occasionally, due to the nature of some contractual restrictions, we are unable to ship a specific product to a particular territory. Jacket images are provisional and liable to change before publication.
|
|
